Pacira BioSciences (PCRX) Change in Accured Expenses (2010 - 2026)

Pacira BioSciences' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 30.07% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $5.4 million (down 65.28% YoY), while the FY2025 annual figure was $6.9 million, down 52.52% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $3.3 million, up from $1.8 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $15.6 million in Q4 2024, with the low at -$24.0 million in Q3 2022.
• The 5-year median for Change in Accured Expenses is $421000.0 (2023), against an average of -$993352.9.
• Peak annual rise in Change in Accured Expenses reached 8630.97% in 2022, while the deepest fall reached 2273.51% in 2022.
• Pacira BioSciences' Change in Accured Expenses stood at $3.7 million in 2022, then plunged by 684.53% to -$21.6 million in 2023, then jumped by 172.21% to $15.6 million in 2024, then slumped by 88.65% to $1.8 million in 2025, then soared by 85.34% to $3.3 million in 2026.
• Business Quant data shows PCRX's Change in Accured Expenses at $3.3 million in Q1 2026, $1.8 million in Q4 2025, and -$5.8 million in Q3 2025.